ClinicalTrials.gg
RecruitingNCT07037511Updated Mar 13, 2026

Effects of Salbutamol in Athletes and Implications for Screening and Sports

An interventional study of Salbutamol and Placebo in Asthma, Healthy and Effect of Drug, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by University of British Columbia · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 72 studies testing albuterol in Asthma — 8 open to participants now, 9 under way, 1 of them phase 3. Albuterol · Asthma.

Planned enrollment
35th of 72
64 · median 63
Started
2025
with 1 other
No phase
17 of 72
3 open now
Registered
70th of 72
by date
Lead sponsor
2 of 72
University of British Columbia

Among the 72 studies testing albuterol in Asthma, this one is the 35th largest by planned enrollment, is one of 2 that started in 2025, is one of 17 with no phase, and was the 70th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

8 of the 72 studies testing albuterol in Asthma are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About albuterol

Albuterol: first FDA approval 1981 (PROVENTIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies testing albuterol in Asthma, or all of them as a file.
02

Study summary

β2-Agonists, commonly used to treat asthma, have also been used by athletes to enhance performance, leading to their ban by the International Olympic Committee in 1972. Research has shown non-asthmatics receive no benefit from these drugs at therapeutic dosages; however, many elite athletes still use them, and asthmatic athletes often win more Olympic medals. In some non-asthmatics, β2-agonists may improve breathing limitations during high intensity exercise, which may improve performance. Therefore, we aim to examine if there is a select group of non-asthmatic individuals who experience breathing limitations that may receive benefit from β2-agonists.

Read the detailed description

Purpose:

The purpose of this study is to examine the effects of β2-agonists on exercise performance in non-asthmatic male and female endurance athletes.

Hypothesis:

Our primary hypothesis is that ß2-agonists will improve exercise duration to a greater degree in athletes who experience expiratory flow limitation (EFL) compared to those who do not experience EFL. Additionally, female athletes will, on average, experience greater benefits with ß2-agonists due to a greater prevalence of EFL than males.

Justification:

While β2-agonists have historically been used by athletes as an ergogenic aid, systematic reviews indicate their ineffectiveness in improving aerobic performance. Consequently, the World Anti-Doping Agency (WADA) revised regulations to allow controlled use of specific β2-agonists. Despite a lack of evidence supporting their ergogenic benefits, positive tests for supratherapeutic doses of salbutamol among elite athletes, such as cyclist Chris Froome and cross-country skier Martin Johnsrud Sundby, suggests a belief in their performance-enhancing capabilities. Additionally, there is a physiological rationale for some non-asthmatics to benefit from these drugs. For instance, therapeutic doses of β2-agonists can induce bronchodilation, resulting in a \~5% increase in forced expiratory volume in one second (FEV1) in non-asthmatics. While this level of bronchodilation does not meet the diagnostic threshold for asthma, it holds potential for enhancing ventilatory responses in certain athletes. For example, a subset of non-asthmatic athletes who develop EFL during exercise, characterized by the inability to increase expiratory flows despite increases in expiratory effort, may derive greater benefits if the bronchodilation is sufficient to attenuate EFL. Indeed, experimental reduction of EFL via breathing a helium-oxygen gas mixture improves ventilatory responses, gas exchange, and endurance performance in non-asthmatics. We speculate that non-asthmatics experiencing EFL during exercise are likely to benefit more from β2-agonists than those who do not develop EFL.

Statistical Analysis:

The effects of salbutamol vs. placebo on exercise duration in all participants will be compared using a paired t-test. In all cases, a P-value \< 0.05 will be considered statistically significant. A total of 64 participants (32 males and 32 females) will be recruited to adequately assess the effects of salbutamol on exercise tolerance, dyspnea, and related physiological variables.

03

Conditions studied

  • Asthma
  • Healthy
  • Effect of Drug

Browse trials for

Keywords

  • Exercise Physiology
  • Expiratory Flow Limitation
  • Non-Asthmatics
  • Beta2-Agonists
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aerobic capacity (V̇O2max) greater than 120% predicted
  • (BMI) > 18 and \< 30 kg/m2
  • Ability to read and understand English
  • Currently training and/or competing in endurance sports (i.e. running or cycling)

Exclusion criteria

Exclusion Criteria:

  • Smoking history or currently smoking. Currently smoking is defined as regular use of cigarettes or cannabis at any point in the past year. History of smoking is defined as smoking more than 1 pack year for cigarettes or the equivalent in cannabis use measured as puffs per day / 200 (number of puffs in a pack of cigarettes).
  • Use of cannabis within the past 30 days or has a smoking history of at least 1 pack year.
  • Use of vaping devices or e-cigarettes in the past 30 days, or has used them more than 10 times in their lifetime.
  • History or current symptoms of cardiopulmonary disease (excluding controlled asthma)
  • to exercise testing defined as anything that would prevent exercise under proper and safe conditions (e.g., a problem with the heart or lungs, muscle)
  • Neuromuscular or musculoskeletal condition
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Active comparator
    Salbutamol inhaler

    Participants will take four inhalations of salbutamol, with 60 seconds between each inhalation, totaling a therapeutic dose of 400µg of salbutamol prior to performing an incremental cardiopulmonary exercise test.

    Drug: Salbutamol

  • Placebo comparator
    Placebo inhaler

    Participants will take four inhalations of placebo, with 60 seconds between each inhalation, prior to performing an incremental cardiopulmonary exercise test.

    Drug: Placebo

Interventions

  • DrugAlbuterolStudies of AlbuterolAlbuterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Meter-dose inhaler of salbutamol performed using large-volume spacer

  • DrugPlacebo

    Meter-dose inhaler of placebo performed using large-volume spacer

06

What researchers measure

Primary outcomes

  1. Difference in time to exhaustion following salbutamol inhalation compared to placebo inhalation.

    Exercise duration will be measured during a time to exhaustion cardiopulmonary exercise test on a stationary cycle ergometer or treadmill.

    Time frame: Up to 2 weeks

  2. Sex differences in time to exhaustion following salbutamol inhalation

    Exercise duration will be measured during a time to exhaustion cardiopulmonary exercise test on a stationary cycle ergometer or treadmill. Sexes will be compared within modality.

    Time frame: Up to 2 weeks

Secondary outcomes

  1. To examine the effects of salbutamol on expiratory flow limitation in endurance athletes

    Expiratory flow limitation will be assessed by placing the tidal flow-volume loop within the maximal flow-volume loop during incremental cardiopulmonary exercise testing on a stationary cycle ergometer or treadmill.

    Time frame: Up to 2 weeks

  2. To explore sex differences in dyspnea following salbutamol inhalation.

    Dyspnea will be assessed during and after both incremental and time to exhaustion cardiopulmonary exercise testing on a stationary cycle ergometer or treadmill with salbutamol.

    Time frame: Up to 2 weeks

  3. To examine ventilatory responses of male and female endurance athletes to exercise with salbutamol.

    Ventilatory responses will be measured continuously throughout both incremental and time to exhaustion cardiopulmonary exercise testing on a stationary cycle ergometer or treadmill using a metabolic cart.

    Time frame: Up to 2 weeks

  4. To explore the effects of salbutamol on exercise duration and expiratory flow limitation in both asthmatic and non-asthmatic individuals.

    A Eucapnic Voluntary Hyperpnea (EVH) test will be performed to assess airway hyperresponsiveness and classify participants as EVH-positive or EVH-negative. All participants will undergo the same cardiopulmonary exercise testing on a stationary cycle ergometer or a treadmill with salbutamol.

    Time frame: Up to 2 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2029, 50 months after the start.

Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 50 months is above that.

Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2025
First posted
Jun 25, 2025
StartActual
Oct 30, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2030
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07037511
Responsible party
Jordan Guenette (Professor, University of British Columbia) — Principal investigator
First posted
Jun 25, 2025
Start date
Oct 30, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Mar 13, 2026

Study contacts

Satvir S Dhillon, MSc
Contact
satvir.dhillon@hli.ubc.ca
604-806-8835
Jordan A Guenette, PhD
Contact
jordan.guenette@hli.ubc.ca
604-806-8835
Jordan A Guenette, PhD
principal investigator · University of British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albuterol

Start the discussion